Clinical trials
Phase 1/2 Leukemia, B-Cell trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 11 |
| Recruiting | 3 |
| Withdrawn | 2 |
| Not yet recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Chongqing Precision Biotech Co., Ltd | 4 |
| AstraZeneca | 2 |
| Chinese PLA General Hospital | 2 |
| Shenzhen Geno-Immune Medical Institute | 2 |
| 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 1 |
| Affiliated Hospital to Academy of Military Medical Sciences | 1 |
| Hebei Senlang Biotechnology Inc., Ltd. | 1 |
| Kunming Hope of Health Hospital | 1 |
| Nanfang Hospital, Southern Medical University | 1 |
| Shanghai GeneChem Co., Ltd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, B-Cell | 18 |
| Lymphoma, B-Cell | 12 |
| Leukemia | 4 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 |
| Lymphoma | 4 |
| Lymphoma, Mantle-Cell | 2 |
| Recurrence | 2 |
| Burkitt Lymphoma | 1 |
| Lymphoma, Follicular | 1 |
| Lymphoma, Large B-Cell, Diffuse | 1 |
Trials
Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.